Should Azithromycin 1g be abandoned as a treatment for bacterial sexually transmitted infections?:The case for and against by Horner, Paddy J & Saunders, John
                          Horner, P. J., & Saunders, J. (2016). Should Azithromycin 1g be abandoned
as a treatment for bacterial sexually transmitted infections?: The case for and
against. Sexually Transmitted
Infections. DOI: 10.1136/sextrans-2015-052414
Peer reviewed version
License (if available):
Unspecified
Link to published version (if available):
10.1136/sextrans-2015-052414
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via BMJ Publishing at http://sti.bmj.com/content/early/2016/07/14/sextrans-2015-052414. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
1 
 
Should Azithromycin 1g be abandoned as a treatment for bacterial 
sexually transmitted infections? The case for and against. 
 
Dr Patrick Horner1,2, Dr John Saunders3 
 
1School of Social and Community Medicine, University of Bristol, United Kingdom.  
2National Institute for Health Research Health Protection Research Unit (NIHR HPRU)  in Evaluation of 
Interventions in partnership with Public Health England, University of Bristol, United Kingdom 
3HIV & STI Department, National Infection Service, Public Health England 
Key Words: Azithromycin, Chlamydia trachomatis, Mycoplasma genitalium, Syphilis 
Corresponding author: Dr Patrick Horner,  School of Social and Community Medicine, University of 
Bristol, Oakfield House, Oakfield Grove,  BS8 2BN,  United Kingdom.  
Email: Paddy.horner@bristol.ac.uk 
Acknowledgment: The NIHR Health Protection Research Unit in Evaluation of Interventions at the 
University of Bristol. The views expressed are those of the authors and not necessarily those of the 
NHS, the NIHR, the Department of Health or Public Health England. 
 
“The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf 
of all authors, an exclusive licence (on non exclusive for government employees) on a worldwide 
basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in STI and 
any other BMJPGL products and sub-licences such use and exploit all subsidiary rights, as set out in 
our licence http://group.bmj.com/products/journals/instructions-for-authors/licence-forms”. 
 
Running Title: Azithromycin 1g use and bacterial STI treatment 
  
2 
 
Where did it all go wrong? Azithromycin, a second generation macrolide antimicrobial, has been 
demonstrated to be highly efficacious both in vitro (low minimum inhibitory concentration (MIC) and 
in vivo against the common bacterial sexually transmitted infections Chlamydia trachomatis (CT), 
Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG) and has good treponemicidal activity 
in animal studies.1 2, W1 2015 CDC guidelines, W2 European guideline Syphilis  What’s more its long 
half-life particularly intracellularly enabled it to be administered as single dose directly observed 
therapy, the preferred dosing schedule for STIs where poor compliance, and thus potential reduced 
efficacy, was considered a major concern with multidose regimens.3  Indeed its efficacy against 
chlamydia was considered to be so good a test of cure was not considered necessary.  
I argue that the evidence indicates that azithromycin 1g is no longer at least 95% effective in achieving 
microbiological cure for bacterial STIs as recommended by WHO for first line treatment and therefore 
should not be used for treatment.4  In addition, as monotherapy, it is likely to be doing harm by 
inducing macrolide antimicrobial resistance. First, it is necessary to consider the mode of action and 
pharmacokinetics of azithromycin given as a 1 g stat regimen (Figure 1) and its mechanism of action; 
second, the mechanism of macrolide antimicrobial development and third, reappraise the evidence 
of efficacy in vivo against the common bacterial STIs, NG , syphilis, CT MG and non-gonococcal 
urethritis (NGU).  
Azithromycin is a bacteriostatic antibiotic and duration of exposure to levels > MIC 90 are likely to be 
important in determining microbiological cure, particularly if the micro-organism is slow growing.5 6  
Although there is limited evidence on the pharmacokinetics of azithromycin in genito-urinary tract 
secretions, it is not unreasonable to consider serum concentrations as a proxy for these. Thus 1g is 
present intracellularly for at least 10 days at an MIC >90% for chlamydia but probably only 6 days 
extracellularly for MG which replicates, slowly, both intracellularly and extracellularly (Figure 1).1 2 7 
Due to the slow clearance of azithromycin surviving bacteria could potentially be exposed to sub-MIC 
levels for prolonged periods of time which may promote emergence of antimicrobial resistance.7 
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A single mutation in the 23S rRNA gene confers antimicrobial resistance to azithromycin.5 7 
Spontaneous genomic mutations are constantly occurring in bacteria,, such that it is likely single 
nucleotide changes that confer high-level antimicrobial resistance would also be likely to be randomly 
present in bacterial populations prior to treatment – heteroresistance.5 8 Bacteria hunt in packs and if 
you have one STI you are more likely to have another, which may not be apparent either because the 
infection is incubating and undetectable (syphilis), or is not detected because it has not been tested 
for. Thus treatment of one bacterial STI  increases the risk of other bacterial STIs being exposed to 
azithromycin.  
NG, utilising all known mechanisms of antimicrobial resistance, has developed antimicrobial resistance 
to all drugs previously and currently recommended for empirical monotherapy of gonorrhoea.9 
(Azithromycin as monotherapy is not recommended and dual antimicrobial therapy is now the 
standard of care.9,W1  Indeed recently there was an outbreak of azithromycin resistance NG in the 
North of England.W3 Azithromycin antimicrobial resistance is now endemic in syphilis and azithromycin 
monotherapy as first line therapy is not recommended.W1, W2 Macrolide antimicrobial resistance  can 
easily develop following exposure.W1, W2 A recent report from Shanghai, where 95% of isolates had 
macrolide antimicrobial resistance, suggested that the development of high levels of macrolide 
antimicrobial resistance may have at least partially been  a consequence of exposure to azithromycin 
or erythromycin prescribed for other bacterial infections.10  
Although Azithromycin 1g treatment of chlamydia in a recent meta-analysis was demonstrated to be 
94% effective, this dropped to ~90% in men with chlamydia urethritis and <90% in rectal infection.11 
Recent evidence strongly suggests the majority of women with genito-urinary infection are co-
infected in the rectum.12-14 Whether treatment failure from rectal infection with subsequent auto-
inoculation of the genitourinary tract contributes to high re-infection rates in women at 3 months 
when treated with azithromycin 1g  is unknown but theoretically possible.15  
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MG is an emerging sexually transmitted infection with a significant morbidity, causing NGU, cervicitis 
(notably post coital bleeding), probably PID and facilitates HIV transmission.2 16  As no diagnostic 
tests are widely available commercially, management is often syndromic using azithromycin 1 g. (W1 
W4) Evidence is accumulating that not only is azithromycin 1g  only 87% efficacious in wild type 
infection but that >10% of wild type infections develop macrolide antimicrobial resistance following 
treatment.   5 17 18  In 2013 1.4 million CT infections were treated in the USA 
(http://www.cdc.gov/std/stats13/chlamydia.htm)of whom probably at least 3% were co-infected 
with MG, if 90% were treated with azithromycin and one assumes 12% developed antimicrobial 
resistance this would equate to production of 4500 separate macrolide resistant isolates, annually, 
which in turn would be transmissible.16 17 Taken together this  could explain Lau et al observations 
that from 2009  the efficacy of azithromycin 1g has dropped from 87% to 67% and why MG 
macrolide antimicrobial resistance appears to be increasing over time and is now prevalent 
worldwide ranging from 20-100%.5 16 18 
In conclusion azithromycin as first line monotherapy is no longer recommended for NG and syphilis. 
Although recommended for chlamydia and NGU, not only may its efficacy in women be <95%, its 
widespread use for treating chlamydia, NGU and their contacts is probably driving the increasing 
prevalence of MG antimicrobial resistance. Currently only two widely available antimicrobials can 
effectively treat MG, second generation macrolides and moxifloxacin.5  Resistance to moxifloxacin is 
also emerging and it is therefore no surprise that dual macrolide and quinolone antimicrobial 
resistance isolates have been identified which are in effect untreatable with currently available 
antibiotics.5  
In my opinion this is an excellent example of how mankind is managing to squander yet another 
precious resource. Azithromycin, a good antibiotic, can no longer be used for treating syphilis and this 
is likely to be the case for MG in the not too distant future.  Commercial tests for MG will become 
more widely available from 2016 in Europe and 2017 in USA (personal communication Hologic). 
Continuing to use azithromycin 1g for the treatment of NGU and chlamydia with its advantages as 
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single dose directly observed therapy and being cheap is storing up problems which will become all 
too evident when testing for MG becomes clinically widely available.  
 
The case against. 
 
Azithromycin meets many of the criteria for the selection of drugs for the treatment of sexually 
transmitted infections as set out by the World Health Organisation.4 It has long been a stalwart of 
national and international guidelines for the treatment of bacterial STIs. However, the future of 
Azithromycin has been called into question with concerns over its efficacy and increasing macrolide 
resistance in several sexually transmitted organisms.19-21 
STI treatment trials using Azithromycin focus predominantly on a 1 gram, single-dose regimen and, 
although some randomised controlled trials have been performed, the majority use observational 
study design. For uncomplicated uro-genital Chlamydia a cure rate of 94% is quoted in the 
metaanalysis by Kong but this is lower when limited to cure rates of symptomatic urethral and rectal 
chlamydia.11 19 Cure rates for Mycoplasma genitalium have steadily fallen over the years with 
countries reporting an increasing proportion of isolates as resistant to Azithromycin.18 A 2010 review 
of single dose Azithromycin, both 1 and 2 grams, for the treatment of gonorrhoea did find high cure 
rates but in an era of little documented macrolide resistance.22 All this has led to a general feeling of 
dissatisfaction with Azithromycin and many clinicians have started to favour the use of alternative 
antibiotics using non-single dose regimen, a move that is also reflected in some national guidelines.23  
Underlying this move away from stat doses in favour of more efficacious, multiple dose alternatives 
is the tacit understanding that we value efficacy more highly than single dose options. If this is true 
then why do we fixate on using 1g stat doses of Azithromycin in clinical trials? Are we not setting it 
up to fail when compared to multiple doses of alternative agents? Recent evidence suggests that five 
days of Azithromycin can effectively eradicate chlamydia with cure rates of 99%.24 The consideration 
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of alternative dosing strategies when designing studies may help to push forward our understanding 
of how best to use Azithromycin and help to expand future treatment options. 
However, several key factors associated with drug adherence may be of particular relevance in the 
treatment of STIs and actually favour the use of stat doses of Azithromycin. Patient factors such as 
younger age, smoking and alcohol use and stigma, fears and anger about the illness have been 
shown to reduce adherence. So too are several treatment-associated factors such as duration of 
treatment, frequency of dosing and requirement for storage.25 Furthermore, the ability to use 
Azithromycin as a stat dose helped to facilitate the widespread rollout of the English National 
Chlamydia Screening Programme which targets sexually active men and women under the age of 25 
years and to whom these key adherence factors are acutely relevant.26 
Although stable, transmitted and increasing levels of macrolide resistance is well documented in 
Neisseria gonorrhoeae, Treponema pallidum and M. genitalium, this is not the case in Chlamydia 
trachomatis with no single nucleotide polymorphisms associated with macrolide resistance having 
been identified in available isolates to date.6 In countries where large quantities of Azithromycin are 
used there has been no evidence of resistance in isolates from those who have failed treatment.27 28 
On the other hand, stable and transmitted tetracycline resistance has been documented in C. suis 
(swine chlamydia) suggesting that a switch to doxycycline may not save us from significant resistance 
issues in the future.29 
Of course, there is no specific need to always use the same antibiotic for each case of an infection; 
an organism may be sensitive to multiple agents. This has been difficult to implement in practice for 
the treatment of STIs as information on the exact organism present and antimicrobial sensitivities 
may not be available immediately. However, this is changing with the expanding field of rapid point 
of care tests to detect both the organism and the presence of antimicrobial resistance. Moving 
forward it will be possible to individualise treatment in a way that has thus far eluded us.30  
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The treatment of STIs in pregnancy is an area where Azithromycin has a key role. In particular, 
chlamydia is associated with numerous adverse sequelae in pregnancy.31-33 Doxycyline is 
contraindicated in pregnancy and other alternatives to Azithromycin are not without significant 
disadvantages. Erythromycin is less than 95% effective and associated with significantly more side 
effects than Azithromycin with 19% of pregnant women discontinuing treatment in one study.34 
Amoxicillin has a better side effect profile and similar cure rates when compared to Erythromycin 
but, in vitro, can induce latency with the re-emergence of infection after treatment has ended 
causing concern.35 Chlamydia is at least as common in young pregnant women as their non-pregnant 
counterparts and new evidence suggests that screening in antenatal clinics is likely cost-effective 
and possibly cost-saving in some situations.36,37 
Not everything about Azithromycin is perfect; no drug is. However, can we afford to throw the baby 
out with the bathwater when we have not fully explored the ways in which we can use 
Azithromycin? Investigating different dosing regimen and the use of cutting edge, rapid diagnostics 
for organisms and potential antimicrobial resistance will allow us to use Azithromycin in more 
intelligent ways. Furthermore, exploring combination therapies for the treatment of chlamydia and 
mycoplasma, as is already common place for gonorrhoea, may also be a useful direction of travel.5 
We cannot abandon the use of Azithromycin for the treatment of bacterial STIs but it is right to 
question the way in which we currently use it. 
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Figure 1 
Figure 1 detailing anticipated serum and tissue concentrations after the administration of 
azithromycin 1g (adapted from Foulds et al.1) and hypothetical change in serum concentration       
5-10 days post administration.  Courtesy of Mr Peter Greenhouse FRCOG 
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